A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects

A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects

This is a phase I, randomised, single-blind, placebo-controlled, first-in-human (FIH) single and multiple ascending dose study consisting of two parts (Part A [SAD] and Part B [MAD]) to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD5718 in healthy male subjects

Study Overview

• Status: Completed
• Conditions: Cardiovascular Disease; Healthy Male Subjects
• Intervention / Treatment: Drug: AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part A); Drug: AZD5718 placebo oral suspension; Drug: AZD5718 oral suspension crystalline form (1 to 100 mg/mL) (Part A); Drug: AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part B)

Detailed Description

This is a phase I, randomised, single-blind, placebo-controlled, first-in-human (FIH) single and multiple ascending dose study consisting of two parts (Part A [SAD] and Part B [MAD]) to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD5718 in healthy male subjects

• Study Type: Interventional
• Enrollment (Actual): 96
• Phase: Phase 1

Contacts and Locations

Study Locations

• United Kingdom
  • Harrow, United Kingdom, HA1 3UJ
    • Research Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 50 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

1. Provision of signed and dated, written informed consent prior to any study specific procedures
2. Healthy male subjects aged 18 - 50 years, inclusive, with suitable veins for cannulation or repeated venepuncture
3. Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive
4. Provision of signed, written and dated informed consent for optional genetic research

Exclusion Criteria:

1. History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study
2. History or presence of gastrointestinal (GI), hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs
3. Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the administration of investigational medicinal product (IMP)

4. Any clinically significant abnormalities in clinical chemistry, haematology, or urinalysis results at screening and check-in, as judged by the investigator, including:

   • Alanine aminotransferase (ALT) > upper limit of normal (ULN);
   • Aspartate aminotransferase (AST) > ULN;
   • Bilirubin (total) > ULN; and
   • Gamma glutamyl transpeptidase (GGT) > ULN
5. Any positive result on screening for serum hepatitis B surface antigen (HBsAg), hepatitis C antibody and human immunodeficiency virus (HIV)
6. Suspicion or known Gilbert's syndrome

7. Abnormal vital signs, after 10 minutes supine rest, at screening and check-in, defined as any of the following:

   • Systolic blood pressure(BP) (SBP) < 90mmHg or ≥ 140 mmHg;
   • Diastolic BP (DBP) < 50mmHg or ≥ 90 mmHg; and
   • Pulse < 45 or > 85 beats per minute (bpm)
8. Any clinically significant abnormalities (at screening and check-in) in rhythm, conduction or morphology of the resting ECG and any clinically significant abnormalities in the 12-lead ECG, as considered by the investigator that may interfere with the interpretation of QTc interval changes, including abnormal ST-T-wave morphology, particularly in the protocol defined primary lead or left ventricular hypertrophy
9. Prolonged QTcF (QT interval corrected for heart rate using Fridericia's formula) > 450 ms or shortened QTcF < 340 ms or family history of long QT syndrome, at screening and check-in
10. PR(PQ) interval (ECG interval measured from the onset of the P wave to the onset of the QRS complex) shortening < 120 ms (PR > 110 ms but < 120 ms is acceptable if there is no evidence of ventricular pre-excitation), at screening and check-in
11. PR (PQ) interval prolongation (> 240 ms) intermittent second (Wenckebach block while asleep is not exclusive) or third degree AV block, or AV dissociation, at screening and check-in
12. Persistent or intermittent complete bundle branch block (BBB), incomplete bundle branch block (IBBB), or intraventricular conduction delay (IVCD) with QRS > 110 ms. Subjects with QRS > 110 ms but < 115 ms are acceptable if there is no evidence of, for example, ventricular hypertrophy or pre-excitation, at screening and check-in
13. Known or suspected history of drug abuse, as judged by the investigator
14. Current smokers or those who have smoked or used nicotine products within the 3 months prior to screening
15. Any history of alcohol abuse or excessive intake of alcohol, as judged by the investigator
16. Positive screen for drugs of abuse, alcohol or cotinine (nicotine) at screening or admission to the unit
17. History of severe allergy/hypersensitivity or ongoing clinically significant allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD5718
18. Excessive intake of caffeine containing drinks or food (e.g., coffee, tea, chocolate), as judged by the investigator
19. Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks prior to the first administration of IMP
20. Use of any prescribed or non-prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to the administration of IMP or longer if the medication has a long half-life
21. Plasma donation within 1 month of screening or any blood donation/blood loss > 500 mL during the 3 months prior to screening
22. Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of the administration of IMP in this study. The period of exclusion is 3 months after the final dose from a previous study
23. Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order
24. Involvement of any AstraZeneca, PAREXEL or study site employee or their close relatives
25. Judgment by the investigator that the subject should not participate in the study if they have any ongoing or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions and requirements
26. Subjects who are vegans or have medical dietary restrictions

27. Subjects who cannot communicate reliably with the investigator

    In addition, any of the following is regarded as a criterion for exclusion from the genetic research:

28. Previous bone marrow transplant
29. Non-leukocyte depleted whole blood transfusion within 120 days of the date of the genetic sample collection

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

17

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: AZD5718 amorphous form, treatment 1 (Part A); Starting dose 25 mg/day, single ascending dose	Drug: AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part A); Single and multiple doses; Drug: AZD5718 placebo oral suspension; Single and multiple doses
Experimental: AZD5718 amorphous form, treatment 2 (Part A); Single dose of AZD5718 amorphous suspension	Drug: AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part A); Single and multiple doses; Drug: AZD5718 placebo oral suspension; Single and multiple doses
Experimental: AZD5718 amorphous form, treatment 3 (Part A); Single dose of AZD5718 amorphous suspension	Drug: AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part A); Single and multiple doses; Drug: AZD5718 placebo oral suspension; Single and multiple doses
Experimental: AZD5718 amorphous form, treatment 4 (Part A); Single dose of AZD5718 amorphous suspension	Drug: AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part A); Single and multiple doses; Drug: AZD5718 placebo oral suspension; Single and multiple doses
Experimental: AZD5718 amorphous form, treatment 5 (Part A); Single dose of AZD5718 amorphous suspension	Drug: AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part A); Single and multiple doses; Drug: AZD5718 placebo oral suspension; Single and multiple doses
Experimental: AZD5718 amorphous form, treatment 6 (Part A); Single dose of AZD5718 amorphous suspension	Drug: AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part A); Single and multiple doses; Drug: AZD5718 placebo oral suspension; Single and multiple doses
Experimental: AZD5718, crystalline form, treatment 7 (Part A); Crystalline suspension (Part A), dosage lower than highest dose used with amorphous suspension, single ascending dose	Drug: AZD5718 placebo oral suspension; Single and multiple doses; Drug: AZD5718 oral suspension crystalline form (1 to 100 mg/mL) (Part A); Oral suspension single dose
Experimental: AZD5718 crystalline form, treatment 8 (Part A); Crystalline suspension (Part A), dosage lower than highest dose used with amorphous suspension, single ascending dose	Drug: AZD5718 placebo oral suspension; Single and multiple doses; Drug: AZD5718 oral suspension crystalline form (1 to 100 mg/mL) (Part A); Oral suspension single dose
Experimental: AZD5718 amorphous form, treatment 1 (Part B); Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)	Drug: AZD5718 placebo oral suspension; Single and multiple doses; Drug: AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part B); Single and multiple doses
Experimental: AZD5718 amorphous form, treatment 2 (Part B); Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)	Drug: AZD5718 placebo oral suspension; Single and multiple doses; Drug: AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part B); Single and multiple doses
Experimental: AZD5718 amorphous form, treatment 3 (Part B); Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)	Drug: AZD5718 placebo oral suspension; Single and multiple doses; Drug: AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part B); Single and multiple doses
Experimental: AZD5718 amorphous form, treatment 4 (Part B); Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)	Drug: AZD5718 placebo oral suspension; Single and multiple doses; Drug: AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part B); Single and multiple doses
Experimental: AZD5718 amorphous/crystalline form, repeat 1 (Part A); Single dose of AZD5718 amorphous form (Part A) Crystalline form (Part A), dosage lower than highest dose used with amorphous form, single ascending dose	Drug: AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part A); Single and multiple doses; Drug: AZD5718 placebo oral suspension; Single and multiple doses; Drug: AZD5718 oral suspension crystalline form (1 to 100 mg/mL) (Part A); Oral suspension single dose
Experimental: AZD5718 amorphous/crystalline form, repeat 2 (Part A); Single dose of AZD5718 amorphous form (Part A) Crystalline form (Part A), dosage lower than highest dose used with amorphous form, single ascending dose	Drug: AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part A); Single and multiple doses; Drug: AZD5718 placebo oral suspension; Single and multiple doses; Drug: AZD5718 oral suspension crystalline form (1 to 100 mg/mL) (Part A); Oral suspension single dose
Experimental: AZD5718 amorphous/crystalline, repeat 3 (Part A); Single dose of AZD5718 amorphous form (Part A) Crystalline form (Part A), dosage lower than highest dose used with amorphous form, single ascending dose	Drug: AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part A); Single and multiple doses; Drug: AZD5718 oral suspension crystalline form (1 to 100 mg/mL) (Part A); Oral suspension single dose
Experimental: AZD5718 amorphous form, repeat 1 (Part B); Twice daily dosing (Day 1 - 9) and once daily dosing (Day 10), dosage TBD (Part A)	Drug: AZD5718 placebo oral suspension; Single and multiple doses; Drug: AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part B); Single and multiple doses
Experimental: AZD5718 amorphous form, repeat 2 (Part B); Twice daily dosing (Day 1 - 9) and once daily dosing (Day 10), dosage TBD (Part A)	Drug: AZD5718 placebo oral suspension; Single and multiple doses; Drug: AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part B); Single and multiple doses

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety and Tolerability of AZD5718 by Assessment of the Number of Participants With Adverse Events Following Oral Administration of SAD (Part A) and MAD (Part B).	To assess the safety and tolerability of AZD5718 following oral administration of SAD (Part A) and MAD (Part B).	From screening to last followup visit (7-10 days after last dose), up to 6 weeks (Part A) and up to 8 weeks (Part B)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate and Extent of Absorption of AZD5718 by Assessment of the Area Under the Plasma Concentration-curve From Time Zero Extrapolated to Infinity (AUC) for Part A - Amorphous and Crystalline Suspension	To assess area under the concentration-time curve from time zero extrapolated to infinity and was estimated by AUC(0-last) + Clast/λz (Clast - the last observed quantifiable concentration) following a single administration of AZD5718 Amorphous and Crystalline suspension (Part A only)	At post-dose (Days 1 to 3); 0.5, 1, 2, 3, 4, 6, 8, 24, 36 and 48 hours post-dose and folow up (Day 4 - 72 hours post-dose) (Part A only)
Rate and Extent of Absorption of AZD5718 by Assessment of the Area Under Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC) for Part B - Amorphous Suspension	To assess the rate and extent of absorption of AZD5718 by evaluation of the area under plasma concentration-time curve from time zero extrapolated to infinity (AUC) following a single AZD5718 dose on Day 1 and multiple daily dosing on Days 9 or 10 under fasted conditions (Part B)	Day 1 of Part B
Rate and Extent of Absorption of AZD5718 by Assessment of the Area Under the Plasma Concentration-curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-last)) for Part A - Amorphous and Crystalline Suspension	To assess area under the area under the plasma concentration-curve from time zero to the time of last quantifiable concentration (AUC(0-last)) following a single administration of AZD5718 Amorphous and Crystalline suspension (Part A only)	At post-dose (Days 1 to 3); 0.5, 1, 2, 3, 4, 6, 8, 24, 36 and 48 hours post-dose and folow up (Day 4 - 72 hours post-dose) (Part A only)
Rate and Extent of Absorption of AZD5718 by Assessment of the Area Under the Plasma Concentration-curve Over the Dosing Interval (AUC(0-τ)) for Part B - Amorphous Suspension	To assess the rate and extent of absorption of AZD5718 by evaluation of the area under the plasma concentration-curve over the dosing interval (AUC(0-τ)) following a single AZD5718 dose on Day 1 and multiple daily dosing on Days 9 or 10 under fasted conditions (Part B)	Day 1, Day 9 and Day 10 of Part B
Rate and Extent of Absorption of AZD5718 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part A - Amorphous and Crystalline Suspension	To assess observed maximum plasma concentration (Cmax) following a single administration of AZD5718 Amorphous and Crystalline suspension (Part A only)	At post-dose (Days 1 to 3); 0.5, 1, 2, 3, 4, 6, 8, 24, 36 and 48 hours post-dose and folow up (Day 4 - 72 hours post-dose) (Part A only)
Rate and Extent of Absorption of AZD5718 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part B - Amorphous Suspension	To assess the rate and extent of absorption of AZD5718 by evaluation of the observed maximum plasma concentration (Cmax) following a single AZD5718 dose on Day 1 and multiple daily dosing on Days 9 or 10 under fasted conditions (Part B)	Day 1, Day 9 and Day 10 (Part B only)
Rate and Extent of Absorption of AZD5718 by Assessment of the Time to Reach the Observed Maximum Plasma Concentration (Tmax) for Part A - Amorphous and Crystalline Suspension	To assess the time to reach the observed maximum plasma concentration (tmax) following a single administration of AZD5718 Amorphous and Crystalline suspension (Part A only)	At post-dose (Days 1 to 3); 0.5, 1, 2, 3, 4, 6, 8, 24, 36 and 48 hours post-dose and folow up (Day 4 - 72 hours post-dose) (Part A only)
Rate and Extent of Absorption of AZD5718 by Assessment of the Time to Reach the Observed Maximum Plasma Concentration (Tmax) for Part B - Amorphous Suspension	To assess the rate and extent of absorption of AZD5718 by evaluation of the time to reach the observed maximum plasma concentration (tmax) following a single AZD5718 dose on Day 1 and multiple daily dosing on Days 9 or 10 under fasted conditions (Part B)	Day 1, Day 9 and Day 10 (Part B only)
Rate and Extent of Absorption of AZD5718 by Assessment of the Half-life Associated With Terminal Slope of a Semi-logarithmic Plasma Concentration-time Curve (t½λz) for Part A - Amorphous and Crystalline Suspension	To assess Rate and extent of absorption of AZD5718 by assessment of the half-life associated with terminal slope of a semi-logarithmic plasma concentration-time curve (t½λz) following a single administration of AZD5718 Amorphous and Crystalline suspension (Part A only)	At post-dose (Days 1 to 3); 0.5, 1, 2, 3, 4, 6, 8, 24, 36 and 48 hours post-dose and folow up (Day 4 - 72 hours post-dose) (Part A only)
Rate and Extent of Absorption of AZD5718 by Assessment of the Half-life Associated With Terminal Slope of a Semi-logarithmic Plasma Concentration-time Curve (t½λz) for Part B - Amorphous Suspension	To assess the rate and extent of absorption of AZD5718 by evaluation of the half-life associated with terminal slope of a semi-logarithmic plasma concentration-time curve (t½λz) following a single AZD5718 dose on Day 1 and multiple daily dosing on Days 9 or 10 under fasted conditions (Part B)	Day 1 and Day 10 (Part B only)
Rate and Extent of Absorption of AZD5718 by Assessment of the Apparent Total Body Clearance After Extravascular Administration Estimated as Dose Divided by AUC (CL/F) for Part A - Amorphous and Crystalline Suspension	To assess rate and extent of absorption of AZD5718 by assessment of the apparent total body clearance after extravascular administration estimated as dose divided by AUC (CL/F) following a single administration of AZD5718 Amorphous and Crystalline suspension (Part A only)	At post-dose (Days 1 to 3); 0.5, 1, 2, 3, 4, 6, 8, 24, 36 and 48 hours post-dose and folow up (Day 4 - 72 hours post-dose) (Part A only)
Rate and Extent of Absorption of AZD5718 by Assessment of the Apparent Total Body Clearance After Extravascular Administration Estimated as Dose Divided by AUC (CL/F) for Part B - Amorphous Suspension	To assess rate and extent of absorption of AZD5718 by assessment of the Rate and extent of absorption of AZD5718 by assessment of CL/F estimated as dose divided by AUC (for Day 1 only) and dose divided by AUCτ on Day 10 following a single AZD5718 dose on Day 1 and multiple daily dosing on Days 9 or 10 under fasted conditions (Part B)	Day 1 and Day 10 of Part B
Rate and Extent of Absorption of AZD5718 by Assessment of the Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) for Part A - Amorphous and Crystalline Suspension	To assess rate and extent of absorption of AZD5718 by assessment of the apparent volume of distribution during the terminal phase after extravascular administration (Vz/F) following a single administration of AZD5718 Amorphous and Crystalline suspension (Part A only)	At post-dose (Days 1 to 3); 0.5, 1, 2, 3, 4, 6, 8, 24, 36 and 48 hours post-dose and folow up (Day 4 - 72 hours post-dose)
To Evaluate the Relative Bioavailability Between the Amorphous and Crystalline Form of AZD5718 (Part A) by Assessment of AUC for Part A - Amorphous and Crystalline Suspension	To assess the relative bioavailability by AUC between the cohort receiving the crystalline suspension and the corresponding data from the cohort receiving the same dose of the amorphous suspension (Part A only). Crystalline suspension was compared to the reference amorphous suspension. Note: Geometric mean ratios for crystalline/amorphous suspensions were calculated	At post-dose (Days 1 to 3); 0.5, 1, 2, 3, 4, 6, 8,12, 24, 36, and 48 hours post-dose and folow up (Day 4 - 72 hours post-dose)
To Evaluate the Relative Bioavailability Between the Amorphous and Crystalline Form of AZD5718 (Part A) by Assessment of Cmax for Part A - Amorphous and Crystalline Suspension	To assess the relative bioavailability by Cmax between the cohort receiving the crystalline suspension and the corresponding data from the cohort receiving the same dose of the amorphous suspension (Part A only). Crystalline suspension was compared to the reference amorphous suspension. Note: Geometric mean ratios for crystalline/amorphous suspensions were calculated	At post-dose (Days 1 to 3); 0.5, 1, 2, 3, 4, 6, 8, 24, 36 and 48 hours post-dose and folow up (Day 4 - 72 hours post-dose) (Part A only)
Rate and Extent of Absorption of AZD5718 by Assessment of the Accumulation Ratio for AUC(0-τ) (RAC AUC(0-τ)) for Part B - Amorphous Suspension	To assess rate and extent of absorption of AZD5718 by assessment of the Rate and extent of absorption of AZD5718 by assessment of accumulation ratio for AUC(0-τ) (RAC AUC(0-τ)) following a single AZD5718 dose on Day 1 and multiple daily dosing on Days 9 or 10 under fasted conditions (Part B) Accumulation ratio calculated as AUC0-τ Day 10/AUC0-τ Day 1 (first dose) for Part B under fasted condition and presented values for Day 10	Day 1 and Day 9 (Part B only)
Rate and Extent of Absorption of AZD5718 by Assessment of the Accumulation Ratio for Cmax (RAC Cmax) for Part B (Amorphous Suspension) Under Fasted Condition	To assess the rate and extent of absorption of AZD5718 by evaluation of accumulation ratio for Cmax (RAC Cmax) following a single AZD5718 dose on Day 1 and multiple daily dosing on Days 9 or 10 under fasted conditions (Part B). Accumulation ratio calculated as Cmax Day 10/Cmax Day 1 (first dose) for Part B under fasted condition.	Day 1 and Day 9 (Part B only)
Rate and Extent of Absorption of AZD5718 by Assessment of the Temporal Change Parameter in Systemic Exposure (TCP) for Part B (Amorphous Suspension) Under Fasted Condition	To assess rate and extent of absorption of AZD5718 by assessment of the temporal change parameter in systemic exposure (TCP) following a single AZD5718 dose on Day 1 and multiple daily dosing on Days 9 or 10 under fasted conditions (Part B). TCP calculated as AUCτDay10/AUCDay 1 and presented values for Day 10	At Day 10 (Part B only)
Rate and Extent of Absorption of AZD5718 by Assessment of the Effect of Food Following Administration of 180 mg AZD5718 With Food (Part B Day 9) and Fasted (Part B Day 10)	The effect of food was evaluated by the assessment of the PK parameter (Cmax) following multiple daily doses of 180 mg AZD5718 under fasted condition (Part B Day 10) and immediately following a high-fat breakfast (Part B Day 9)	At Day 9 and Day 10 (Part B only)
Rate and Extent of Absorption of AZD5718 by Assessment of the Effect of Food Following Administration of 180 mg AZD5718 With Food (Part B Day 9) and Fasted (Part B Day 10)	The effect of food was evaluated by the assessment of the PK parameter (AUC(0-t) following multiple daily doses of 180 mg AZD5718 under fasted condition (Part B Day 10) and immediately following a high-fat breakfast (Part B Day 9)	At Day 9 and Day 10 (Part B only)
Rate and Extent of Absorption of AZD5718 by Assessment of the Effect of Food Following Administration of 180 mg AZD5718 With Food (Part B Day 9) and Fasted (Part B Day 10)	The effect of food was evaluated by the assessment of the PK parameter(tmax) following multiple daily doses of 180 mg AZD5718 under fasted condition (Part B Day 10) and immediately following a high-fat breakfast (Part B Day 9)	At Day 9 and Day 10 (Part B only)
Rate and Extent of Absorption of AZD5718 by Assessment of Cumulative Amount of Analyte Excreted at the Last Sampling Interval (CumAe0-24) Following a Single Administration of AZD5718 Amorphous and Crystalline Suspension (Part A)	To assess urine PK parameter (CumAe0-24) after a single administration of AZD5718 Amorphous suspension in Part A	Part A pre-dose and pooled intervals up to 24 hours post-dose
Rate and Extent of Absorption of AZD5718 by Assessment of Percentage of Dose Excreted Unchanged Into the Urine From 0 to 24 Hours (Cumfe0-24) Following a Single Administration of AZD5718 Amorphous and Crystalline Suspension (Part A)	To assess urine PK parameter (Cumfe0-24) estimated by dividing Ae(0-last) by dose after a single administration of AZD5718 Amorphous suspension in Part A	Part A pre-dose and pooled intervals up to 24 hours post-dose
Rate and Extent of Absorption of AZD5718 by Assessment of Renal Clearance (CLR) Following a Single Administration of AZD5718 Amorphous and Crystalline Suspension (Part A)	To assess the urine PK parameter (CLR) after a single administration of AZD5718 Amorphous suspension in Part A	Part A pre-dose and pooled intervals up to 24 hours post-dose
Rate and Extent of Absorption of AZD5718 by Assessment of Cumulative Amount of Analyte Excreted From 0 to 24 Hours (CumAe0-24) Following a Multiple Daily Doses Administration of AZD5718 Amorphous Suspension (Part B Day 9)	To assess the urine PK parameter (CumAe0-24) after a single administration of AZD5718 Amorphous suspension in Part B Day 9	Part B only, Day 9 at pooled 3 hour intervals until 24 hours post-dose
Rate and Extent of Absorption of AZD5718 by Assessment of Percentage of Dose Excreted Unchanged Into the Urine From 0 to 24 Hours (Cumfe0-24) Following a Multiple Daily Doses Administration of AZD5718 Amorphous Suspension (Part B Day 9)	To assess urine PK parameter (Cumfe0-24) estimated by dividing Ae(0-last) by dose after a single administration of AZD5718 Amorphous suspension in Part B Day 9	Part B only, Day 9 at pooled 3 hour intervals until 24 hours post-dose
Rate and Extent of Absorption of AZD5718 by Assessment of Renal Clearance (CLR) Following a Multiple Daily Doses Administration of AZD5718 Amorphous Suspension (Part B Day 9)	To assess the urine PK parameter (CLR) after a single administration of AZD5718 Amorphous suspension in Part B Day 9	Part B only, Day 9 at pooled 3 hour intervals until 24 hours post-dose
Pharmacodynamic Analysis by ex Vivo Stimulation of Leukotriene B4 (LTB4) Production Using Calcium Ionophore for Part A -Amorphous and Crystalline Suspension	To assess the change from baseline in the ex vivo stimulated LTB4 production using calcium ionophore in venous blood samples following a single administration of AZD5718 Amorphous and Crystalline suspension (Part A only)	Admission to 0.5, 1, 2, 3, 4, 6, 8, 24, 36 and 48 hours post-dose (Part A only)
Pharmacodynamic Analysis by ex Vivo Stimulation of LTB4 Production Using Calcium Ionophore for Part B - Amorphous Suspension	To assess the change from baseline in the ex vivo stimulated LTB4 production using calcium ionophore in venous blood samples following multiple administration of AZD5718 Amorphous suspension (Part B only)	Admission, predose and 0.5, 1, 2, 3, 4, 6, 8, 24, 36 and 48 hours post-dose

Collaborators and Investigators

• Sponsor: AstraZeneca
• Investigators: Principal Investigator: Annelize Koch, MBChB, FFPM, Parexel

Study record dates

Study Major Dates

• Study Start (Actual): February 10, 2016
• Primary Completion (Actual): August 26, 2016
• Study Completion (Actual): August 26, 2016

Study Registration Dates

• First Submitted: December 7, 2015
• First Submitted That Met QC Criteria: December 14, 2015
• First Posted (Estimate): December 16, 2015

Study Record Updates

• Last Update Posted (Actual): March 21, 2019
• Last Update Submitted That Met QC Criteria: December 12, 2018
• Last Verified: December 1, 2018

More Information

Terms related to this study

• Keywords: Safety; Pharmacokinetics; Placebo-controlled; Tolerability; Pharmacodynamics; AZD5718 oral suspension crystalline; AZD5718 oral suspension amorphous; Single ascending dose/multiple ascending dose (SAD/MAD)
• Additional Relevant MeSH Terms: Cardiovascular Diseases
• Other Study ID Numbers: D7550C00001